MBRX - Moleculin gains 5% on FDA green light for Phase 1 study of WP1122 in glioblastoma multiforme

Moleculin Biotech (NASDAQ:MBRX) perks up 5.3% premarket after FDA allowed its Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward. With this IND now cleared, Moleculin plans to initiate a Phase 1 dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1122 in adult patients with GBM. This new US IND sets the stage for parallel development of WP1122 as a cancer therapy. Moleculin recently announced its plans to initiate a Phase 1a clinical trial of WP1122 in U.K. to facilitate future testing in COVID-19 patients.

For further details see:

Moleculin gains 5% on FDA green light for Phase 1 study of WP1122 in glioblastoma multiforme